Yoshihisa Arao

Dr. Yoshihisa Arao

Niigata University Graduate School of Medical and Dental Sciences
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2012 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
NWNobuo Waguri
Nobuo Waguri
MHMasahiro Hayashi
Masahiro Hayashi
TYTakeshi Yokoo
Takeshi Yokoo
RSRie Sato
Rie Sato
YAYoshihisa Arao
Yoshihisa Arao
TSTakeshi Suda
Takeshi Suda

1 June 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YAYoshihisa Arao
Yoshihisa Arao
HKHirokazu Kawai
Hirokazu Kawai
KKKenya Kamimura
Kenya Kamimura
TKTakamasa Kobayashi
Takamasa Kobayashi
ONOki Nakano
Oki Nakano
STShuji Terai
Shuji Terai

23 January 2023 in Hepatology Research
Verified
Journal Article
Closed access
YWYusuke Watanabe
Yusuke Watanabe
HAHiroyuki Abe
Hiroyuki Abe
NKNaruhiro Kimura
Naruhiro Kimura
YAYoshihisa Arao
Yoshihisa Arao
NINatsuki Ishikawa
Natsuki Ishikawa
STShuji Terai
Shuji Terai

13 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MOMarina Ohkoshi-Yamada
Marina Ohkoshi-Yamada
KKKenya Kamimura
Kenya Kamimura
OSOsamu Shibata
Osamu Shibata
SMShinichi Morita
Shinichi Morita
MKMotoki Kaidu
Motoki Kaidu
STShuji Terai
Shuji Terai
This study investigated the efficacy and safety of radiotherapy as part of multidisciplinary therapy for advanced hepatocellular carcinoma (HCC). Clinical data of 49 HCC patients treated with radiotherapy were assessed retrospectively. The efficacy of radiotherapy was assessed by progression-free survival, disease control rate, and overall survival. Safety was assessed by symptoms and hematological assay, and changes in hepatic reserve function were determined by Child–Pugh score and albumin–bilirubin (ALBI) score. Forty patients underwent curative radiotherapy, and nine patients with portal vein tumor thrombus (PVTT) underwent palliative radiotherapy as part of multidisciplinary therapy. Local disease control for curative therapy was 80.0% and stereotactic body radiotherapy was 86.7% which was greater than that of conventional radiotherapy (60.0%). Patients with PVTT had a median observation period of 651 days and 75% three-year survival when treated with multitherapy, including radiotherapy for palliative intent, transcatheter arterial chemoembolization, and administration of molecular targeted agents. No adverse events higher than grade 3 and no changes in the Child–Pugh score and ALBI score were seen. Radiotherapy is safe and effective for HCC treatment and can be a part of multidisciplinary therapy.

1 May 2019 in Internal Medicine
Verified
Journal Article
Open access
PDF file
YAYoshihisa Arao
Yoshihisa Arao
KKKenya Kamimura
Kenya Kamimura
MIMasatoshi Ikemi
Masatoshi Ikemi
MTMasayuki Takaki
Masayuki Takaki
STShunsaku Takahashi
Shunsaku Takahashi
STShuji Terai
Shuji Terai
Carcinosarcoma is a biphasic malignant tumor comprising both carcinomatous and sarcomatous components; its occurrence in the duodenum is very rare. We herein report the case of a 96-year-old woman with duodenal carcinosarcoma showing rapid growth within the past year. The tumor was found to be bulging into the lumen and predominantly comprised sarcomatoid components with positive focal staining for cytokeratin. Therefore, the tumor was diagnosed as duodenal carcinosarcoma. The clinical information of the present case and our literature review of the 12 cases reported to date will help physicians diagnose and treat this rare tumor.

1 February 2021 in Kanzo
Verified
Journal Article
Open access
PDF file
Masaru EnomotoMasaru Enomoto
Masaru Enomoto
IHIsao Hidaka
Isao Hidaka
TITaisuke Inoue
Taisuke Inoue
HIHiroshi Isoda
Hiroshi Isoda
TITatsuya Ide
Tatsuya Ide
MKMasaaki Korenaga
Masaaki Korenaga
In Japan, each prefecture in collaboration with regional core centers is required to train hepatitis medical care coordinators (HMCCs). In this study, we surveyed the present status of HMCCs in 17 of the 71 regional core centers. The findings indicated that the number of HMCCs varied from 8 to 77 per regional core center. The proportion of HMCCs who actively contributed to hepatitis patient care also varied from 7.9% to 100%. Among the HMCCs, 50% were nurses, 11% clinical laboratory technicians, 8.0% pharmacists, 8.0% registered dietitians, and 3.5% doctors. The results of the survey show that, in each regional core center, there is a substantial variety in the present status of HMCCs.